OPTNライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:41):

Stats
本日の出来高	717 979
平均出来高	1.04M
時価総額	96.19M
EPS	$0 ( 2024-03-07 )
次の収益日	( $-0.110 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.67
ATR14	$0.00400 (0.47%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-18	Krick Anthony J	Sell	2 345	Common Stock
2024-03-15	Marino Michael F Iii	Buy	3 816	Common Stock
2024-03-18	Marino Michael F Iii	Sell	15 059	Common Stock
2024-03-15	Mahmoud Ramy A	Buy	6 114	Common Stock
2024-03-18	Mahmoud Ramy A	Sell	19 198	Common Stock

INSIDER POWER
-24.22
Last 98 transactions
Buy: 6 923 187 \| Sell: 11 541 596

ボリューム相関

長: 0.18 (neutral)

短: -0.18 (neutral)

Signal:(52.689) Neutral

OptiNose Inc 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

OptiNose Inc 相関 - 通貨/商品

0.00
( neutral )

-0.33
( neutral )

OptiNose Inc 財務諸表

Annual	2023
収益:	$70.99M
総利益:	$61.95M (87.27 %)
EPS:	$-0.320

FY	2023
収益:	$70.99M
総利益:	$61.95M (87.27 %)
EPS:	$-0.320

FY	2022
収益:	$76.28M
総利益:	$67.01M (87.86 %)
EPS:	$-0.890

FY	2021
収益:	$74.65M
総利益:	$65.50M (87.74 %)
EPS:	$-1.450

Financial Reports:

No articles found.

OptiNose Inc

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.